RATIONALE: Central dogma suggests that rifampicin resistance in Mycobacterium tuberculosis develops solely through rpoB gene mutations. OBJECTIVE: To determine whether rifampicin induces efflux pumps activation in rifampicin resistant M. tuberculosis strains thereby defining rifampicin resistance levels and reducing ofloxacin susceptibility. METHODS: Rifampicin and/or ofloxacin minimum inhibitory concentrations (MICs) were determined in rifampicin resistant strains by culture in BACTEC 12B medium. Verapamil and reserpine were included to determine their effect on rifampicin and ofloxacin susceptibility. RT-qPCR was applied to assess expression of efflux pump/transporter genes after rifampicin exposure. To determine whether verapamil could restore susceptibility to first-line drugs, BALB/c mice were infected with a MDR-TB strain and treated with first-line drugs with/without verapamil. MEASUREMENTS AND MAIN FINDINGS: Rifampicin MICs varied independently of rpoB mutation and genetic background. Addition reserpine and verapamil significantly restored rifampicin susceptibility (p = 0.0000). RT-qPCR demonstrated that rifampicin induced differential expression of efflux/transporter genes in MDR-TB isolates. Incubation of rifampicin mono-resistant strains in rifampicin (2 μg/ml) for 7 days induced ofloxacin resistance (MIC > 2 μg/ml) in strains with an rpoB531 mutation. Ofloxacin susceptibility was restored by exposure to efflux pump inhibitors. Studies in BALB/c mice showed that verapamil in combination with first-line drugs significantly reduced pulmonary CFUs after 1 and 2 months treatment (p < 0.05). CONCLUSION: Exposure of rifampicin resistant M. tuberculosis strains to rifampicin can potentially compromise the efficacy of the second-line treatment regimens containing ofloxacin, thereby emphasising the need for rapid diagnostics to guide treatment. Efflux pump inhibitors have the potential to improve the efficacy of anti-tuberculosis drug treatment.
RATIONALE: Central dogma suggests that rifampicin resistance in Mycobacterium tuberculosis develops solely through rpoB gene mutations. OBJECTIVE: To determine whether rifampicin induces efflux pumps activation in rifampicin resistant M. tuberculosis strains thereby defining rifampicin resistance levels and reducing ofloxacin susceptibility. METHODS:Rifampicin and/or ofloxacin minimum inhibitory concentrations (MICs) were determined in rifampicin resistant strains by culture in BACTEC 12B medium. Verapamil and reserpine were included to determine their effect on rifampicin and ofloxacin susceptibility. RT-qPCR was applied to assess expression of efflux pump/transporter genes after rifampicin exposure. To determine whether verapamil could restore susceptibility to first-line drugs, BALB/c mice were infected with a MDR-TB strain and treated with first-line drugs with/without verapamil. MEASUREMENTS AND MAIN FINDINGS:Rifampicin MICs varied independently of rpoB mutation and genetic background. Addition reserpine and verapamil significantly restored rifampicin susceptibility (p = 0.0000). RT-qPCR demonstrated that rifampicin induced differential expression of efflux/transporter genes in MDR-TB isolates. Incubation of rifampicin mono-resistant strains in rifampicin (2 μg/ml) for 7 days induced ofloxacin resistance (MIC > 2 μg/ml) in strains with an rpoB531 mutation. Ofloxacin susceptibility was restored by exposure to efflux pump inhibitors. Studies in BALB/c mice showed that verapamil in combination with first-line drugs significantly reduced pulmonary CFUs after 1 and 2 months treatment (p < 0.05). CONCLUSION: Exposure of rifampicin resistant M. tuberculosis strains to rifampicin can potentially compromise the efficacy of the second-line treatment regimens containing ofloxacin, thereby emphasising the need for rapid diagnostics to guide treatment. Efflux pump inhibitors have the potential to improve the efficacy of anti-tuberculosis drug treatment.
Authors: E M Streicher; R M Warren; C Kewley; J Simpson; N Rastogi; C Sola; G D van der Spuy; P D van Helden; T C Victor Journal: J Clin Microbiol Date: 2004-02 Impact factor: 5.948
Authors: Edda De Rossi; Patrizio Arrigo; Marco Bellinzoni; Pedro A E Silva; Carlos Martín; José A Aínsa; Paola Guglierame; Giovanna Riccardi Journal: Mol Med Date: 2002-11 Impact factor: 6.354
Authors: R S Wallis; S Patil; S H Cheon; K Edmonds; M Phillips; M D Perkins; M Joloba; A Namale; J L Johnson; L Teixeira; R Dietze; S Siddiqi; R D Mugerwa; K Eisenach; J J Ellner Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191
Authors: Matt Hoshide; Lishi Qian; Camilla Rodrigues; Rob Warren; Tommie Victor; Henry B Evasco; Thelma Tupasi; Valeriu Crudu; James T Douglas Journal: J Clin Microbiol Date: 2013-06-19 Impact factor: 5.948
Authors: Kristian Angeby; Christian G Giske; Pontus Juréen; Thomas Schön; Jotam G Pasipanodya; Tawando Gumbo Journal: Antimicrob Agents Chemother Date: 2011-09 Impact factor: 5.191